Nicholas Vita - Dec 6, 2023 Form 4 Insider Report for Cannabist Co Holdings Inc. (CBSTF)

Role
Chief Executive Officer, Director
Signature
/s/ Nicholas Vita
Stock symbol
CBSTF
Transactions as of
Dec 6, 2023
Transactions value $
-$211,755
Form type
4
Date filed
12/13/2023, 07:41 PM
Previous filing
Dec 7, 2023
Next filing
Dec 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CBSTF Common Shares Sale -$109K -300K -1.46% $0.36 20.3M Dec 6, 2023 Held by Vita Holdings LLC F1, F4
transaction CBSTF Common Shares Sale -$38.6K -100K -0.49% $0.39 20.2M Dec 7, 2023 Held by Vita Holdings LLC F2, F4
transaction CBSTF Common Shares Sale -$64.5K -150K -0.74% $0.43 20M Dec 11, 2023 Held by Vita Holdings LLC F3, F4
holding CBSTF Common Shares 619K Dec 6, 2023 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales price reported above was converted from the Canadian weighted average price of $0.4917 using an exchange rate of C$1.3574 = US$1.00. These shares were sold in multiple transactions at prices ranging from C$0.48 to $0.51, inclusive. The Reporting Person undertakes to provide to The Cannabist Company Holdings Inc., any security holder of The Cannabist Company Holdings Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2 The sale price reported above was converted from the Canadian sale price of C$0.525 using an exchange rate of C$1.3597 = US$1.00.
F3 The sale price reported above was converted from the Canadian weighted average price of C$0.5833 using an exchange rate of C$1.3570 = US$1.00. These shares were sold in multiple transactions at price ranging from C$0.58 to $0.585, inclusive. The Reporting Person undertakes to provide to The Cannabist Company Holdings Inc., any security holder of The Cannabist Company Holdings Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F4 Shares sold by third-party financial institution in partial satisfaction of debt obligation. Funding was primarily used for pediatric medical research for orphan and ultra rare illnesses, tax payments, education and philanthropic purposes.